SG11201706281YA - Use of plinabulin in combination with immune checkpoint inhibitors - Google Patents
Use of plinabulin in combination with immune checkpoint inhibitorsInfo
- Publication number
- SG11201706281YA SG11201706281YA SG11201706281YA SG11201706281YA SG11201706281YA SG 11201706281Y A SG11201706281Y A SG 11201706281YA SG 11201706281Y A SG11201706281Y A SG 11201706281YA SG 11201706281Y A SG11201706281Y A SG 11201706281YA SG 11201706281Y A SG11201706281Y A SG 11201706281YA
- Authority
- SG
- Singapore
- Prior art keywords
- plinabulin
- combination
- immune checkpoint
- checkpoint inhibitors
- inhibitors
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 title 1
- 229950011498 plinabulin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115468P | 2015-02-12 | 2015-02-12 | |
| US201562255259P | 2015-11-13 | 2015-11-13 | |
| PCT/US2016/017602 WO2016130839A1 (en) | 2015-02-12 | 2016-02-11 | Use of plinabulin in combination with immune checkpoint inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706281YA true SG11201706281YA (en) | 2017-09-28 |
Family
ID=56615698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706281YA SG11201706281YA (en) | 2015-02-12 | 2016-02-11 | Use of plinabulin in combination with immune checkpoint inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180028531A1 (ja) |
| EP (1) | EP3256130A4 (ja) |
| JP (3) | JP7243021B2 (ja) |
| KR (1) | KR20170117113A (ja) |
| CN (2) | CN117100753A (ja) |
| AU (3) | AU2016219204B2 (ja) |
| CA (1) | CA2975729A1 (ja) |
| CL (1) | CL2017002050A1 (ja) |
| HK (1) | HK1247816A1 (ja) |
| IL (2) | IL286282B2 (ja) |
| MX (2) | MX2017010338A (ja) |
| MY (1) | MY193968A (ja) |
| NZ (1) | NZ734256A (ja) |
| RU (1) | RU2723021C2 (ja) |
| SG (1) | SG11201706281YA (ja) |
| WO (1) | WO2016130839A1 (ja) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| CN107530341B (zh) | 2015-03-06 | 2021-10-01 | 大连万春布林医药有限公司 | 治疗与ras突变相关的癌症的方法 |
| JP6904570B2 (ja) | 2015-03-06 | 2021-07-21 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 脳腫瘍の治療方法 |
| AU2016275574B2 (en) * | 2015-06-11 | 2019-07-11 | Bionomics Limited | Pharmaceutical combination and uses thereof |
| BR112018000229A2 (pt) | 2015-07-13 | 2018-09-04 | Beyondspring Pharmaceuticals Inc | composições de plinabulina |
| SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| AU2017278245B2 (en) | 2016-06-06 | 2022-09-15 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
| EP3505183B1 (en) * | 2016-08-26 | 2022-03-30 | Tetsuji Okuno | Microvascular blood flow decreasing agent and use thereof |
| CN110072552A (zh) * | 2016-10-14 | 2019-07-30 | 默沙东公司 | 用于治疗尿路上皮癌的pd-1拮抗剂和艾立布林的组合 |
| CN110431135A (zh) | 2017-01-06 | 2019-11-08 | 大连万春布林医药有限公司 | 微管蛋白结合化合物及其治疗用途 |
| KR20190109479A (ko) | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| DK3595653T3 (da) * | 2017-03-13 | 2023-04-17 | Beyondspring Pharmaceuticals Inc | Sammensætninger af plinabulin og anvendelse heraf |
| CA3066360C (en) | 2017-07-26 | 2022-05-17 | Chong Kun Dang Pharmaceutical Corp. | Combination for preventing or treating cancer comprising a vascular disrupting agent and immune checkpoint inhibitor |
| EP3678669A4 (en) * | 2017-09-08 | 2021-06-09 | University Health Network | POLYTHERAPIES TO INHIBIT POLO-TYPE KINASE 4 |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| JP7350015B2 (ja) | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
| US20210161888A1 (en) * | 2018-06-01 | 2021-06-03 | Beyondspring Pharmaceuticals, Inc. | Composition and method of treating cancer associated with egfr mutation |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| CN112638388A (zh) * | 2018-08-16 | 2021-04-09 | 大连万春布林医药有限公司 | 刺激免疫反应的方法和组合物 |
| EP3873504B1 (en) * | 2018-11-01 | 2023-12-13 | North Carolina State University | Adipocyte mediated delivery of anticancer therapeutics |
| CN110265095A (zh) * | 2019-05-22 | 2019-09-20 | 首都医科大学附属北京佑安医院 | 用于hcc复发及rfs的预测模型和诺模图的构建方法及应用 |
| CN112778155B (zh) * | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
| JP2023524530A (ja) * | 2020-05-04 | 2023-06-12 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法 |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| US20240197723A1 (en) * | 2021-04-09 | 2024-06-20 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100540548C (zh) * | 2002-08-02 | 2009-09-16 | 尼瑞斯药品公司 | 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成 |
| EP1711487A1 (en) * | 2004-02-04 | 2006-10-18 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| ES2427646T5 (es) * | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
| US8569262B2 (en) * | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| EP2962731A1 (en) * | 2008-01-08 | 2016-01-06 | Bristol-Myers Squibb Company | Combination of ipilimumab and paclitaxel for the treatment of cancer |
| CA2774015A1 (en) * | 2009-09-15 | 2011-03-24 | Cerulean Pharma Inc. | A cdp-camptothecin conjugate, particle or composition and uses thereof |
| US20130064831A1 (en) * | 2010-05-17 | 2013-03-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| WO2013090552A1 (en) * | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| CA2889182A1 (en) * | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| RU2708032C2 (ru) * | 2013-02-20 | 2019-12-03 | Новартис Аг | ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII |
| KR20160013049A (ko) * | 2013-06-03 | 2016-02-03 | 노파르티스 아게 | 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물 |
| WO2015051543A1 (en) * | 2013-10-11 | 2015-04-16 | Dalian Wanchun Biotechnology Co., Ltd. | Cancer treatment with combination of plinabulin and taxane |
-
2016
- 2016-02-11 EP EP16749903.7A patent/EP3256130A4/en active Pending
- 2016-02-11 SG SG11201706281YA patent/SG11201706281YA/en unknown
- 2016-02-11 CN CN202311274843.6A patent/CN117100753A/zh active Pending
- 2016-02-11 RU RU2017127966A patent/RU2723021C2/ru active
- 2016-02-11 NZ NZ734256A patent/NZ734256A/en unknown
- 2016-02-11 WO PCT/US2016/017602 patent/WO2016130839A1/en active Application Filing
- 2016-02-11 MY MYPI2017702826A patent/MY193968A/en unknown
- 2016-02-11 MX MX2017010338A patent/MX2017010338A/es unknown
- 2016-02-11 CA CA2975729A patent/CA2975729A1/en active Pending
- 2016-02-11 AU AU2016219204A patent/AU2016219204B2/en active Active
- 2016-02-11 JP JP2017560890A patent/JP7243021B2/ja active Active
- 2016-02-11 IL IL286282A patent/IL286282B2/en unknown
- 2016-02-11 CN CN201680015268.XA patent/CN107427510A/zh active Pending
- 2016-02-11 US US15/550,350 patent/US20180028531A1/en active Pending
- 2016-02-11 KR KR1020177025140A patent/KR20170117113A/ko not_active Application Discontinuation
-
2017
- 2017-08-01 IL IL253784A patent/IL253784B/en unknown
- 2017-08-10 MX MX2022007472A patent/MX2022007472A/es unknown
- 2017-08-10 CL CL2017002050A patent/CL2017002050A1/es unknown
-
2018
- 2018-05-31 HK HK18107194.9A patent/HK1247816A1/zh unknown
-
2021
- 2021-01-07 JP JP2021001505A patent/JP7157181B2/ja active Active
- 2021-04-21 AU AU2021202416A patent/AU2021202416B2/en active Active
-
2022
- 2022-11-01 JP JP2022175377A patent/JP2022190005A/ja active Pending
-
2024
- 2024-02-02 AU AU2024200672A patent/AU2024200672A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286282A (en) | Use of palinabolin in combination with immune checkpoint inhibitors | |
| HK1243072A1 (zh) | 布羅莫結構域抑制劑及其用途 | |
| PL3186281T3 (pl) | Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej | |
| EP3233123A4 (en) | Use of immune checkpoint inhibitors in central nervous systems neoplasms | |
| IL251051A0 (en) | mk2 inhibitors and their uses | |
| PL3231605T3 (pl) | Laminat elastyczny i zawierający go artykuł | |
| GB201617085D0 (en) | Compare and delay instructions | |
| HK1254954A1 (zh) | Lpt-723和免疫檢查點抑制劑組合物及其治療方法 | |
| HUE051268T2 (hu) | Immunellenõrzõpont-gátló kombinációk | |
| PL3078489T3 (pl) | Elastyczny laminat i zawierający go wyrób | |
| HK1243077A1 (zh) | 呱啶基吡唑並嘧啶酮及其用途 | |
| IL266116A (en) | Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use | |
| HK1250926A1 (zh) | 抑制劑及其應用 | |
| HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
| PT3204190T (pt) | Artigo abrasivo texturizado e métodos relacionados | |
| PT2944309T (pt) | Utilização de palmitoiletanolamida em combinação com opióides | |
| GB201506127D0 (en) | Immune checkpoint inhibitor combinations | |
| GB2530075B (en) | Improvements in and relating to eyewashing | |
| PL3229772T3 (pl) | 6-arylo-9-glikozylopuryny i ich zastosowanie | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| GB201417432D0 (en) | Improvements in and relating to pipe-breaking | |
| GB201412345D0 (en) | Improvements in and relating to devices | |
| GB201409978D0 (en) | Novel compounds and their use in therapy |